女性HPV感染与宫颈鳞状上皮内病变

目的 研究女性HPV感染与其宫颈鳞状上皮内病变关系,为临床预防宫颈癌发生发展提供基础数据.方法 537例HPV感染阳性患者样本来源于解放军第210医院妇科门诊,分析患者感染HPV基因亚型与数量及患者年龄数据,研究其与患者宫颈鳞状上皮内病变统计学关系.结果 单一高危亚型HPV感染患者宫颈鳞状上皮内病变发病率高于单一低危亚型HPV感染患者,差别有统计学意义(P＜0.05).单一高危亚型HPV感染患者4种具体宫颈鳞状上皮内病变发病率均高于低危亚型HPV感染患者,其中ASC-H及LSIL发病率差别有统计学意义(P＜0.05).不同类型多重HPV感染患者宫颈鳞状上皮内病变发病率差别未见统计学意义(P＞0.05).多重HPV感染患者宫颈鳞状上皮内病变发病率高于单一HPV感染患者,差别有统计学意义(P＜0.05).多重HPV感染患者ASC-US发病率高于单一HPV感染患者,差别有统计学意义(P＜0.05).HPV感染患者宫颈鳞状上皮内病变发病率在41 ～ 50年龄组最高,65.04％(80/123),与其它各年龄组比较差别均有统计学意义(P＜0.05).结论 HPV感染基因亚型种类、数量及感染者年龄均与宫颈鳞状上皮内病变发生有一定关联,其中高危亚型HPV感染、多重HPV感染与中年妇女三种因素,与宫颈鳞状上皮内病变发生发展关系密切.     

HPV高危型别检测联合细胞学检查对宫颈病变筛查的研究

目的 研究人乳头瘤病毒HPV高危型别检测联合液基薄层细胞学检查（TCT）及阴道镜检查对宫颈癌及癌前病变筛查的诊断价值。方法 对1375例宫颈组织细胞样本进行HPV高危型别检测,对其中阳性样本进行TCT检查,有宫颈上皮内瘤变者（CIN）行阴道镜下活检病理组织学确诊。HPV高危型别检测采用双色荧光定量PCR方法进行8种高危型HPV DNA（主要高危型：HPV16,18,45,31）和次要高危型（HPV33,52,58,67）分型及病毒载量检测。结果 1375例样本高危型HPV DNA检测结果为阳性256例,阳性率为18.62％;TCT结果为WNL的样本高危型HPV的感染率为16.41％ （42/256）;TCT结果为ASCUS以上的样本高危型HPV的感染率为83.59％（ 214/256）。HPV各型别的病毒载量在TCT结果为WNL、ASCUS及LSIL/HSIL/SCC之间差异无统计学意义（P＞0.5）。TCT与阴道镜的阳性符合率分别为WNL-正常或炎症92.86％（ 39/42）,LISL-CIN I 81.36％（48/59）,HSIL-CIN Ⅱ＆Ⅲ 85.19％ （23/27）,SCC-宫颈癌9/10。结论 HPV高危型别检测联合TCT技术及阴道镜检查能显著提高宫颈病变的阳性检出率,可作为宫颈癌及宫颈上皮内瘤变（ CIN）筛查的可靠早期诊断方法,具有重要临床应用价值。     

细胞DNA倍体分析对宫颈高度鳞状上皮内病变诊断及随访价值研究

目的探讨细胞DNA倍体分析对宫颈高度鳞状上皮内病变HSIL+的诊断价值及HSIL-的随访意义。方法收集2013年1月至2014年12月在中山市博爱医院常规行宫颈癌筛查的妇女共1576例,均行液基细胞学检查(TCT)+细胞DNA倍体分析。任一结果阳性均行阴道镜活检,定义病理结果≥HSIL为病理阳性,HSIL为病理阴性。结合TCT及活检病理结果,分析细胞DNA倍体分析诊断HSIL+的价值及细胞DNA倍体分析对HSIL-的随访价值。结果 (1)1576例受检妇女细胞DNA倍体分析阳性率15.6%,TCT阳性率9.33%。阴道镜转诊率21.45%。(2)不同病理分级DNA异倍体细胞数(N)差异有统计学意义(χ2=259.5,P=0.000)。细胞DNA异倍体数(N)与宫颈病变严重程度呈正相关(r=5.322,P=0.000)。各年龄分组中细胞DNA倍体分析阳性率差异有统计学意义(χ~2=173.224,P0.01)。(3)细胞DNA倍体分析敏感度81.03%,TCT敏感度32.76%,差异有统计学意义(χ2=27.559,P0.01);细胞DNA倍体分析联合TCT检测敏感度可达87.93%。(4)对病理阴性患者随访2年可知,细胞DNA倍体阳性患者较阴性患者罹患HSIL+的风险高(P0.05)。结论细胞DNA倍体分析在宫颈癌筛查中对HSIL+的诊断及HSIL-的随访均有较高的临床价值,细胞DNA倍体分析联合TCT用于宫颈癌初筛优于单独的筛查方法。     

The relationship between the HR-HPV load and cervical lesions in Chaozhou area

目的 探讨高危型人乳头瘤病毒(high risk human papillomavirus,HR-HPV)载量与宫颈病变级别之间的关系.方法 采用RT-PCR对农村35～60岁女性进行HR-HPV DNA定量检测并记录CT值,2 731例阳性者再进行核酸分子快速导流杂交分型技术(HybriMax)和液基薄层细胞学(thinprep liquid-based cytologic test,LCT)检查;对低级别鳞状上皮内病变(low grade squamous intraepithelial lesion,LSIL)及以上病变行阴道镜下组织病理学活检.根据LCT及病理活检结果按病变级别分成5组:无上皮内瘤变或恶性病变(non-squamous intraepithelial lesion or neoplasia,NILM)、未明确诊断意义的不典型鳞状上皮细胞(atypical squamous cells of undetermined significance,ASCUS)、LSIL、高级别鳞状上皮内病变(high grade squamous intraepithelial lesion,HSIL)和鳞状细胞癌(squamous cell cacinoma,SCC).在同级别宫颈病变中,按照HPV感染的类型分为4组:HPV52、HPV16、HPV58和多重HPV感染.采用方差分析的方法对各组平均CT值进行统计分析.结果 随宫颈病变级别的升高,CT均值降低,5组CT均值间差异均具有显著性(P＜0.05).在同级别宫颈病变中,NILM组HPV58和多重HPV差异有显著性(P＜0.05),ASCUS组HPV16和多重HPV差异有显著性,其余病变级别各HPV感染组间差异均无显著性(P＞0.05).结论 HR-HPV载量与宫颈病变级别呈正相关,高HR-HPV载量是影响宫颈病变级别的危险因素.     

TCT检测联合DNA倍体分析在宫颈病变中的研究探讨

目的：探讨TCT检测联合DNA倍体分析对宫颈病变的诊断价值。方法收集2010年1月~2014年1月,我院妇产科收治的子宫良性病变患者158例,均在术前接受宫颈液基薄层细胞学检测(TCT)以及DNA倍体分析,并以术后病理诊断作为标准,统计两种方法的诊断阳性率。结果本组158例患者经TCT检查显示,阳性率为62.0%,其中,49例确诊为CIN及宫颈癌,准确率为50.0%;经DNA倍体分析显示,50例存在异常倍体,阳性检出率为31.6%,其中38例为CIN及宫颈癌,准确率为76.0%。结论TCT联合DNA倍体分析对宫颈病变早期筛查与诊断具有重要意义,值得推广应用。     

HPV分型检测联合TCT检查在宫颈病变筛查中的应用

目的 探究人乳头瘤病毒（HPV）以及液基细胞学（TCT）的联合检测在宫颈病变的筛查中的应用。方法 选取2015 年12月~2016年11月因宫颈异常来我院就诊的2327例妇科疾病患者,对其实施TCT以及HPV DNA检测,对阳性的患者进行阴道镜活检,以患者组织的病理学结果作为最终确诊标准。结果 共计355例患者进行阴道镜检查,其中HPV检测灵敏度为75.72%,准确性为70.43%,特异性为30.22%;TCT检测灵敏度为41.32%,准确性43.40%,特异性为47.87%;二者联合诊断灵敏度为88.21%,准确率75.10%,特异性为43.36%。两种检测方法的阳性检出敏感度相比,差异有统计学意义（P＜0.05）。结论 HPV分型检测联合TCT的检测方式具有相当高的阳性率及灵敏度,能够提高患者宫颈病变的检出率,延长患者的筛查间隔,有利于临床上对于宫颈病变的筛查。     

TCT、高危型HPV检测筛查诊断宫颈癌及癌前病变的病理学对照研究

目的:研究液基薄层细胞学检测(Thinprep cytologic test,TCT)、高危型人乳头瘤状病毒(Human papillomavirus,HPV)检测筛查诊断宫颈癌及癌前病变的病理学对照.方法:回顾性分析2020年1月至2021年1月期间于我院进行宫颈癌筛查的127例女性患者临床资料,分别进行TCT、高危型HPV、宫颈组织检测.以病理学结果为金标准,对比TCT、高危型HPV检出率以及诊断准确度、灵敏度、特异度、阳性预测值、阴性预测值.结果:经检查127例进行宫颈癌筛查女性经宫颈活体组织检查确诊为宫颈病变者51例,其中LSIL19例、HISL32例;宫颈癌患者9例;其余67例未发现宫颈癌及癌前病变.TCT检出37例,检出率为61.67％;高危型HPV检出40例,检出率为66.67％,组间比较差异无统计学意义(P>0.05).TCT检测的灵敏度、特异度、准确度、阳性预测值、阳性预测值略低于高危型HPV检测,但组间比较差异无统计学意义((P>0.05).结论:TCT、高危型HPV检测在宫颈癌及癌前病变筛查中具有重要价值,临床可根据患者个人情况进行选择.     

DNA倍体分析联合HPV-DNA23分型检测对ASC-US的诊断价值

目的探讨DNA倍体分析联合HPV-DNA 23分型检测(HPV检测)对子宫颈液基细胞学涂片(liquid-based preparation, LBP)报告的"不能明确意义的非典型鳞状细胞(atypical squamous cells of undetermined significance, ASC-US)"的诊断价值。方法收集64例ASC-US子宫颈细胞样本,制成LBP薄片2张,1张用于巴氏染色进行LBP TBS分级诊断,1张用于Feulgen染色进行DNA倍体分析,同样方法进行HPV检测;检测结果经子宫颈组织活检验证。结果 64例ASC-US经活检验证,其中22例阴性,为正常或炎症;42例阳性,包括低级别鳞状上皮内病变(low-grade squamous intraepithelial lesion, LSIL)21例、高级别鳞状上皮内病变(high-grade squamous intraepithelial lesion, HSIL)+癌(鳞状细胞癌1例)21例,阳性率为65.63%。在42例病理结果阳性中:DNA倍体分析和HPV检测共阳性22例,占比34.38%(22/64);DNA倍体分析或HPV检测阳性20例,占比31.25%(20/64);在21例HSIL+癌中,DNA倍体分析或HPV检测阳性6例,占比9.38%(6/64)。在22例病理结果阴性中:DNA倍体分析+HPV检测共阳性4例,占比6.25%(4/64);DNA倍体分析或HPV检测阳性15例,占比23.44%(15/64);DNA倍体分析+HPV检测共阴性3例,占比4.69%(3/64)。结论在LBP诊断ASC-US病例中,其DNA倍体分析和(或)HPV检测阳性时建议转诊阴道镜;而DNA倍体分析和HPV检测共阴性时建议采用常规LBP复查。DNA倍体分析联合HPV检测对子宫颈LBP筛查报告中的ASC-US病例具有辅助诊断价值。     

妊娠与高危型人乳头瘤病毒感染易感性的相关分析

目的探讨妊娠对高危型人乳头瘤病毒感染率及宫颈病变的影响。方法采用第二代杂交捕获法(HC-Ⅱ)检测60例非孕妇女、60例妊娠妇女不同妊娠时期、产后3月HPV感染率,宫颈脱落细胞薄层液基细胞学检查(TCT)及阴道镜检查。结果妊娠晚期HPV感染率最高(46.7%),妊娠早中期感染率次之(21.7%),产后3个月下降(16.7%),非妊娠期感染率8%,随着妊娠进展,HPV感染率也在不断的增加,各期TCT检查结果比较差异无统计学意义(P>0.05)。结论妊娠对高危型HPV感染的易感性的升高有相关性,应加强孕前、孕期宫颈病变的筛查。     

HPV-DNA与TCT联合检测在宫颈早期病变筛查中的相关性研究

目的 探讨新柏氏液基薄层细胞学(TCT)技术联合HPV- DNA检测在宫颈早期病变筛查中的相关性.方法 对2008年9月至2011年7月来我院妇科门诊就诊的375例HPV- DNA阳性患者行TCT检测,采取TBS报告方式,将TCT与HPV- DNA结果对进行照分析.结果 375例HPV- DNA阳性患者TCT检查者,结果良性反应性改变273例(72.8％),ASC阳性者84例(22.4％),LSIL阳性6例(1.6％),HSIL阳性12例(3.2％),HPV高危亚型感染率分别为69.23％、92.86％、100％、100％.结论 TCT联合HPV- DNA检测可提高宫颈早期病变的诊断率.     

液基细胞学联合DNA定量细胞学在筛查宫颈病变中的应用价值

目的探讨宫颈液基细胞学和DNA定量细胞学在宫颈癌前病变及宫颈癌诊断中的应用价值。方法对2156例患者进行宫颈液基细胞学和DNA定量细胞学检查,对其中221例液基细胞学和（或）DNA定量分析阳性者行宫颈活检,以活检结果为金标准,比较两种方法的检测结果及DNA定量细胞学对ASCUS患者的分流作用。结果1．液基细胞学以≥ASCUS,DNA定量细胞学以可见DNA倍体异常细胞作为活检标准及联合两种方法检测,活检结果以CINI及以上病理改变作为阳性结果,其敏感度、特异度、阳性预测值、阴性预测值分别为69．77％、77．52％和89．15％,38．04％、48．91％和84．09％,61．22％、63．69％和86．47％,47．30％、60．81％和84．09％。2．TCT与DNA定量细胞学检测方法灵敏度及特异度对比,均无统计学意义（P〉0．05）;TCT联合应用DNA定量细胞学与单独应用TCT检测方法灵敏度及特异度对比,均有统计学意义（P〈0．01）;TCT联合应用DNA定量细胞学与单独应用DNA定量细胞学检测方法灵敏度对比,无统计学意义（P〉0．05）,特异度对比,有统计学意义（P〈0．01）。3．ASCUS患者宫颈病变的检出率为56．25％。ASCUS患者以DNA定量细胞学作为分流方法：阳性组检出率为74．00％,阴性组检出率为26．67％,两组检出率对比,有高度统计学差异（P〈0．01）;DNA定量细胞学阳性组与ASCUS患者未分流前检出率对比,有统计学意义（P〈0．05）。结论DNA定量分析方法与液基薄层细胞学联合筛查,可提高宫颈癌前病变及宫颈癌筛查的敏感度和特异度,对于细胞学检测为ASCUS的人群有分流作用。     

TCT联合细胞DNA定量分析在桂西壮族妇女宫颈病变诊断中的应用

目的探讨宫颈液基薄层细胞学检查(TCT)联合DNA定量分析在桂西壮族妇女宫颈病变筛查中的价值。方法选取同时行TCT、细胞DNA定量分析和活组织病理学检查的430例资料进行分析。宫颈脱落细胞液基薄层制片,1张巴氏染色做TCT诊断,1张Feulgen染色,应用全自动细胞图像分析系统扫描诊断。结果以活检结果作为诊断的金标准,TCT、DNA定量分析和联合检测的检出率分别为64.2%、90.6%和96.2%。联合检测与单独DNA定量分析检出率比较,差异不显著(P>0.05),联合检测与单独TCT的检出率比较,TCT与DNA定量分析的检出率比较,差异均显著(P<0.01)。结论 DNA定量分析检出率高于TCT,二者联合应用并不能有效地提高宫颈病变的检出率。     

高危型HPV阳性患者宫颈支原体和衣原体感染与宫颈组织学改变的关系

目的 探讨高危型HPV阳性不孕患者宫颈支原体和衣原体感染与宫颈组织病变的关系.方法 以HPV阴性不孕患者为对照,回顾分析不同高危型别HPV阳性不孕患者宫颈支原体和衣原体感染与宫颈组织病理分级、炎症分级之间的关系.结果 支原体阳性者HPV感染的发生率与支原体阴性者差异有统计学意义（P＜0.01）,衣原体阳性者HPV感染的发生率与衣原体阴性者差异无统计学意义（P＞0.05）.与HPV阴性组比较,HPV阳性者CIN和宫颈糜烂发生率以及CIN分级均较高（P＜0.01）,HPV阳性者宫颈糜烂程度无差异（P＞0.05）.与单纯HPV阳性组比较,HPV和支原体混合感染者CIN发生率及重度宫颈糜烂无差异（P＞0.05）.结论 支原体感染增加了高危型HPV的感染概率,高危型HPV感染增加了宫颈组织的病理损害程度,支原体感染可能是高危型HPV持续性感染的因素,宫颈组织病理程度是宫颈性不孕不可忽视的因素.     

Prevalence and genotype distribution of human papillomavirus in non-neoplastic cervical tissue lesion: cervical erosion

Human papillomavirus (HPV) infection is the commonest sexually transmitted infection, which is associated with various clinical conditions, ranging from asymptomatic infection to malignant disease of the cervix. The aim of this study was to evaluate the prevalence and genotypic distribution of HPV in women with cervical erosion and to compare the results with those in women with a clinically normal cervix. A further aim was to establish the association between HPV infection and cervical cytology results in women with and without cervical erosion. Cervical samples were collected by liquid-based method and consecutively evaluated for the presence of HPV DNA and for cervical cytology. HPV DNA was tested by a nested polymerase chain reaction (PCR) and typed by reverse dot blot genotyping. Cytological classification was made according to Bethesda 2001 criteria. The overall HPV prevalence was 16.9%; HPV DNA was positive in 20.2% of women with cervical erosion and 12.8% in women with normal cervix (P < 0.05). Multiple infections were found in 34.1% of the HPV-positive women. Commonest types were HPV 18 (32.9%), HPV 16 (29.5%), HPV 54 (20.5%), and HPV 6 (17%). Cervical cytology results were abnormal for 5.2% of women with cervical erosion and for 1.3% with clinically normal cervix (P < 0.05). This study detected a high prevalence of HPV infection in women with cervical erosion compared to women with a normal cervix. This data may contribute to the HPV epidemiology in the southeastern Turkey. It is recommended that women with cervical erosion should be given priority in HPV screening programs.     

Clinicopathological Implications of Human Papilloma Virus (HPV) L1 Capsid Protein Immunoreactivity in HPV16-Positive Cervical Cytology

Background: The objective of this study was to investigate the expression of human papilloma virus (HPV) L1 capsid protein in abnormal cervical cytology with HPV16 infection and analyze its association with cervical histopathology in Korean women.Material and Methods: We performed immunocytochemistry for HPV L1 in 475 abnormal cervical cytology samples from patients with HPV16 infections using the Cytoactiv^® HPV L1 screening set. We investigated the expression of HPV L1 in cervical cytology samples and compared it with the results of histopathological examination of surgical specimens.Results: Of a total of 475 cases, 188 (39.6%) were immunocytochemically positive and 287 (60.4%) negative for HPV L1. The immunocytochemical expression rates of HPV L1 in atypical squamous cells of unknown significance (ASCUS), low-grade squamous intraepithelial lesions (LSIL), high-grade squamous intraepithelial lesions (HSIL), and cancer were 21.8%, 59.7%, 19.1%, and 0.0%, respectively. LSIL exhibited the highest rate of HPV L1 positivity. Of a total of 475 cases, the multiple-type HPV infection rate, including HPV16, in HPV L1-negative cytology samples was 27.5%, which was significantly higher than that in HPV L1-positive cytology samples (p = 0.037). The absence of HPV L1 expression in ASCUS and LSIL was significantly associated with high-grade (≥cervical intraepithelial neoplasia [CIN] 2) than low-grade (≤CIN1) histopathology diagnoses (p < 0.05), but was not significantly different between HPV16 single and multiple-type HPV infections (p > 0.05). On the other hand, among 188 HPV L1-positive cases, 30.6% of multiple-type HPV infections showed high-grade histopathology diagnoses (≥CIN3), significantly higher than the percentage of HPV16 single infections (8.6%) (p = 0.0004)Conclusions: Our study demonstrates that the expression of HPV L1 is low in advanced dysplasia. Furthermore, the absence of HPV L1 in HPV16-positive low-grade cytology (i.e., ASCUS and LSIL) is strongly associated with high-grade histopathology diagnoses. The multiplicity of HPV infections may have an important role in high-grade histopathology diagnoses (≥CIN3) in HPV L1-positive cases.     

Telomerase and human papillomavirus as diagnostic adjuncts for cervical dysplasia and carcinoma

Telomerase and human papillomavirus (HPV) DNA were evaluated as potential markers of high-grade dysplasia in cervical cytological specimens. Cytology specimens were collected from patients at the time of colposcopic evaluation for management of a previous abnormal cytology test result. Telomerase activity was evaluated by the telomeric repeat amplification protocol (TRAP), and HPV DNA was detected by polymerase chain reaction with L1 consensus-sequence primers and filter hybridization genotyping. Telomerase was detected in 8 of 97 (8.2%) cases with normal cytology or benign cellular changes, in 7 of 98 (7.1%) cases of atypical squamous cells of undetermined significance (ASCUS), in 3 of 95 (3.2%) cases of low-grade squamous intraepithelial lesion (LSIL), and in 17 of 48 (35.4%) cases with high-grade squamous intraepithelial lesion (HSIL). High-risk HPVs were detected in 23 of 97 (23.7%) cases with normal/reactive cellular changes (RCC) cytology, in 28 of 98 (28.6%) cases of ASCUS, in 69 of 95 (72.6%) cases of LSIL, and in 35 of 48 (72.9%) cases of HSIL. Telomerase expression did not correlate with the detection of high-risk HPVs in any cytological diagnostic categories. Telomerase and HPV test results of cytological specimens were correlated with the histological diagnoses of concurrent cervical biopsy specimens. Telomerase showed a sensitivity of 29.9% and a specificity of 94.0% for biopsy-confirmed cervical intraepithelial neoplasia (CIN) II/III. In contrast, high-risk HPVs were detected in 70.1% of cases with underlying CIN II/III, with a specificity of 62.5%. A relatively high proportion of normal/RCC or ASCUS cases with telomerase-positive test results had underlying high-grade dysplasia on cervical biopsy. Thus, technical and practical limitations of the TRAP assay in cervical cytology specimens limit the practical application of telomerase as a diagnostic adjunct in cervical cytopathology.